2022
DOI: 10.1186/s43162-022-00176-y
|View full text |Cite
|
Sign up to set email alerts
|

A systematic review of epidermal growth factor receptor tyrosine kinase inhibitor-induced heart failure and its management

Abstract: Background Multiple case reports and case series have been published on heart failure due to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs), yet the management and outcome of the said disease have been scarcely discussed in sufficient details. This review is aimed at characterizing the signs, symptoms, laboratory parameters, and outcomes of this entity by analyzing recent published case reports and case series reporting new-onset heart failure in non-small cell lung can… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2023
2023
2025
2025

Publication Types

Select...
4

Relationship

0
4

Authors

Journals

citations
Cited by 4 publications
(1 citation statement)
references
References 44 publications
0
1
0
Order By: Relevance
“…In a systematic review of case reports and a series describing EGFR-TKI-induced heart failure in NSCLC, osimertinib was administered in 82.6 % of the cases [ 10 ], implying that heart failure due to osimertinib is more likely to develop than heart failure due to other EGFR-TKIs (afatinib, erlotinib, and gefitinib). Moreover, the frequency of osimertinib-induced cardiotoxicity is higher than that of other EGFR-TKIs.…”
Section: Discussionmentioning
confidence: 99%
“…In a systematic review of case reports and a series describing EGFR-TKI-induced heart failure in NSCLC, osimertinib was administered in 82.6 % of the cases [ 10 ], implying that heart failure due to osimertinib is more likely to develop than heart failure due to other EGFR-TKIs (afatinib, erlotinib, and gefitinib). Moreover, the frequency of osimertinib-induced cardiotoxicity is higher than that of other EGFR-TKIs.…”
Section: Discussionmentioning
confidence: 99%